ofranergene obadenovec (VB-111)

News alerts, weekly reports and conference planners

Company:

NANO MRNA, VBL Therap

Drug class:

Angiogenesis inhibitor, Vascular disrupting agent

Related drugs:

No biomarker	Glioblastoma	No biomarker	Glioblastoma	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B	VB-111 Sensitive: B - Late Trials VB-111 Sensitive : B

Associations
(2)